

Joining together to improve overall survival in oncogenic-driven NSCLC

Monday 22 October 2018, 13:00–14:30

Hall A1 – Room 16, Messe Munich, Munich, Germany



Chair's invitation

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium **‘Joining together to improve overall survival in oncogenic-driven NSCLC’**.

Improving survival is undisputedly critical for patients with oncogenic-driven non-small cell lung cancer (NSCLC), and is also a key objective for treating physicians. As the range of treatment options for oncogenic-driven NSCLC increases, so does the need to carefully consider the evidence for sequencing of treatments in order to optimise survival outcomes.

During the symposium, our distinguished faculty will discuss EGFR-positive, ROS1-positive and ALK-positive NSCLC and will focus on the available overall survival evidence in order to understand what these data can tell us about treatment selection and sequencing. We will also listen to the patient's perspective from LuCE (Lung Cancer Europe) to develop our understanding of the needs and goals of patients, to help our patients remain at the centre of every treatment decision.

My colleagues and I look forward to welcoming you in Munich for what promises to be an interesting and engaging symposium.

Tony Mok, Chair

Li Shu Fun Medical Foundation The Chinese University of Hong Kong, Hong Kong

Programme

Chair: **Tony Mok (Hong Kong)**

13:00–13:05	Welcome and introduction	Tony Mok (Hong Kong)
13:05–13:30	The role of treatment selection and sequencing in survival outcomes: A focus on EGFR-positive NSCLC	Tony Mok (Hong Kong)
13:30–13:55	The role of treatment selection and sequencing in survival outcomes: A focus on ALK and ROS1-positive NSCLC	Benjamin Besse (France)
13:55–14:10	Being heard over the noise: The patient's viewpoint	LuCE (Lung Cancer Europe)
14:10–14:30	Panel discussion: Reflections on NSCLC overall survival	All faculty, facilitated by Tony Mok (Hong Kong)